Promace-C-Mopp in Aggressive Non-Hodgkin's Lymphoma Long-Term Results in 45 Patients Treated in a Single Institution

References

• DeVita VT, Jr, Canellos G P, Chabner B, Schein P, Hubbard S P, Young RC. Advanced diffuse histiocytic lymphoma, a potentially curable disease: results with combination chemotherapy. Lancet 1975; 1: 248–50
   PubMed Web of Science ®Google Scholar
• Armitage J O, Corder M P, Leimert J T, Dick F R, Elliott TE. Advanced diffuse histiocytic lymphoma treated with Cyclophosphamide, Doxorubicin, Vincristine and Predinsone (CHOP) without maintenance therapy. Cancer Treat Rep 1980; 64: 649–54
   PubMedGoogle Scholar
• Lee R, Cabanillas F, Bodey G P, Freireich EJ. A 10-year update of CHOP-bleo in the treatment of diffuse large-cell lymphoma. J Clin Oncol 1989; 4: 1455–61
   Google Scholar
• Gaynor E R, Ultmann J E, Golomb H M, Sweet DL. Treatment of diffuse histiocytic lymphoma (DHL) with COMLA (Cyclophosphamide. Oncovin, Methotrexate. Leucovorin, Cy-tosine Arabinoside): a 10-year experience in a single institution. J Clin Oncol 1985; 3: 1596–604
   PubMed Web of Science ®Google Scholar
• Coleman M. Chemotherapy for large-cell lymphoma: optimism and caution. Ann Intern Med 1985; 103: 140–2
   PubMed Web of Science ®Google Scholar
• Skarin AT. Diffuse aggressive lymphomas: a curable subset of non-Hodgkin's lymphomas. Semin Oncol 1986; 13: 10–25, Suppl 5
   PubMedGoogle Scholar
• Goldie H, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to the spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727–33
   PubMedGoogle Scholar
• Fisher R I, DeVita VT, Jr, Hubbard S M, et al. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy. Ann Intern Med 1983; 98: 304–9
   PubMed Web of Science ®Google Scholar
• Skarin A T, Canellos G P, Rosenthal D S, et al. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high-dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol 1983; 1: 91–8
   PubMed Web of Science ®Google Scholar
• Laurence J, Coleman M, Allen S L, Silver R T, Pasmantier M. Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen. Ann Intern Med 1982; 97: 190–5
   PubMed Web of Science ®Google Scholar
• Longo D, DeVita V, Duffey P, et al. Randomized trial of ProMACE-MOPP (day [D] 1, D 8) (PM) vs ProMACE-CytaBOM (PC) in stage II-IV aggressive non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 1987; 6: 206
   Google Scholar
• Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 1985; 102: 596–602
   PubMed Web of Science ®Google Scholar
• Boyd D B, Coleman M, Papish S W, et al. COPBLAM III: infusional combination chemotherapy for diffuse large-cell lymphoma. J Clin Oncol 1988; 6: 425–33
   PubMed Web of Science ®Google Scholar
• Armitage J O, Cheson BD. Interpretation of clinical trials in diffuse large-cell lymphoma. J Clin Oncol 1988; 6: 1335–47
   PubMed Web of Science ®Google Scholar
• The Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112–35
   PubMed Web of Science ®Google Scholar
• Velasquez W S, Fuller L M, Jagannath S. Diffuse large cell lymphomas: stages III and IV in adults. Hodgkin's disease and non-Hodgkin's lymphomas in adults and children, L M Fuller, F B Hagemeister, M P Sullivan, W S Velasquez. Raven Press, New York 1988; 346–64
   Google Scholar
• Hryniuk W. The importance of dose intensity in outcome of chemotherapy. Important advances in oncology, V T DeVita, S Hellman, S A Rosenberg. Lippincott, Philadelphia 1988; 121–43
   Google Scholar
• Dixon D O, McLaughlin Hagemeister F B, et al. Reporting outcomes in Hodgkin's disease and lymphoma. J Clin Oncol 1987; 5: 1670–2
   PubMed Web of Science ®Google Scholar
• Kaplan E L, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–81
   Web of Science ®Google Scholar
• Gehan EA. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 1965; 52: 203–23
   PubMed Web of Science ®Google Scholar
• Surbone A, Longo D L, De Vita V T, et al. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management. J Clin Oncol 1988; 6: 1832–7
   PubMed Web of Science ®Google Scholar
• WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. WHO, Geneva 1979
   Google Scholar
• Fisher R I, Young R C, Longo D, DeVita VT. ProMACE-MOPP combination chemotherapy for diffuse lymphomas. Semin Oncol 1985; 12: 29–32, Suppl 2
   PubMed Web of Science ®Google Scholar
• Coiffier B, Gisselbrecht C, Herbrecht R, Tilly H, Bosly A, Brousse N. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 1989; 7: 1018–26
   PubMed Web of Science ®Google Scholar
• Dahlberg S, Miller T P, Dana B, Weick J, Fisher RI. Dose intensity is not associated with subsequent survival after adjustment for known prognostic factors in non-Hodgkin's lymphoma patients treated with m-BACOD, ProMACE-CytaBOM and MACOP-B in Southwest Oncology Group studies. Proc ASCO 1990; 9: 255
   Google Scholar
• Yi P I, Coleman M, Saltz L, et al. Chemotherapy for large cell lymphoma: a status update. Semin Oncol 1990; 17: 60–73
   PubMed Web of Science ®Google Scholar
• Shipp M A, Harrington D P, Klatt M M, et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med 1986; 104: 757–65
   PubMed Web of Science ®Google Scholar
• Federico M, Gobbi P G, Barbieri F, Silingardi V. Relationship between prognostic factors and therapy in high-grade non-Hodgkin's lymphomas over two decades. Haematologica 1989; 74: 511–9
   PubMedGoogle Scholar
• Danieu L, Wong G, Koziner B, Clarkoh B. Predictive model for prognosis in advanced diffuse histiocytic lymphoma. Cancer Res 1986; 46: 5372–9
   PubMed Web of Science ®Google Scholar
• Simon R, Durrleman S, Hoppe R T, et al. Prognostic factors for patients with diffuse large cell or immunoblastic non-Hodgkin's lymphomas: experience of the Non-Hodgkin's Lymphoma Pathologic Classification Project. Med Pediatr Oncol 1990; 18: 89–96
   PubMedGoogle Scholar
• Fisher R I, Miller T B, Dana B W, et al. Southwest Oncology Group Clinical trials for intermediate and high-grade non-Hodgkin's lymphomas. Semin Hematol 1988; 25: 17–22
   PubMedGoogle Scholar
• Shipp M A, Yeap B Y, Harrington D P, et al. The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen. J Clin Oncol 1990; 8: 84–93
   PubMed Web of Science ®Google Scholar